Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes
Luyu Xie, Diego Anazco, Azucena Herrera Chancay, M. Sunil Mathew, Jackson M. Francis, Jaime P. Almandoz, Sarah E. Messiah
TL;DR
This study examines how often people without diabetes switch GLP-1 receptor agonists and how long they stick with the treatment.
Contribution
The study provides new insights into treatment persistence and switching behaviors of GLP-1 receptor agonists in non-diabetic adults.
Findings
Switching between GLP-1 receptor agonists is common within 12 months of treatment initiation.
Treatment persistence rates vary significantly depending on the initial GLP-1 receptor agonist prescribed.
Abstract
This cohort study evaluates glucagon-like peptide-1 (GLP-1) receptor agonist switching patterns and 12-month adherence and persistence among adults with overweight or obesity without diabetes.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetes Treatment and Management · Medication Adherence and Compliance · Bariatric Surgery and Outcomes